Novo Nordisk A/S shares dropped 5.4% on Thursday after a U.S. law firm filed a class action lawsuit against the Danish pharmaceutical company on behalf of the Lehigh County Employees’ Retirement System in Pennsylvania. The complaint, filed by Bernstein Litowitz Berger & Grossmann LLP, alleges Novo Nordisk “reported materially false and misleading earnings and forecasts in that they were inflated through the collusive price fixing of the company’s insulin drugs.” The complaint also alleges the drug maker “misrepresented and concealed the true extent of the pricing pressures it was experiencing from pharmacy benefit managers.” Novo Nordisk is the world’s largest insulin maker for the treatment of diabetes. The lawsuit covers the time between April 30, 2015 to Oct. 27, 2016.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Latest posts by Market Watch (see all)
- Market Extra: How some ‘Trump trades’ have performed as he nears his 100th day in office - April 27, 2017
- Market Extra: Dow rally from election to Trump’s first 100 days on track for postwar record - April 27, 2017
- Personal Finance Daily: The latest American status symbol and how adding calorie counts makes us healthier - April 27, 2017